Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenib |
| |
| Authors: | Andrea Casadei-Gardini Giulia Rovesti Vincenzo Dadduzio Caterina Vivaldi Eleonora Lai Sara Lonardi Lorenzo Fornaro Andrea Pretta Vittorina Zagonel Laura Bernardini Giorgio Astara Francesco E. D'Amico Gianluca Masi Margherita Rimini Mario Scartozzi Stefano Cascinu |
| |
| Affiliation: | 1. Department of Medical Oncology, Università Vita-Salute, San Raffaele Hospital IRCCS, 20019, Milan, Italy;2. Department of Oncology and Hematology, Division of Oncology, University of Modena and Reggio Emilia, 4121, Modena, Italy;3. Medical Oncology Unit 1, Veneto Institute of Oncology IRCCS, Padua, Italy;4. Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Via savi 10, 56126, Pisa PI, Italy;5. Medical Oncology Unit, University Hospital and University of Cagliari, Cagliari, Italy;6. U.O. Oncologia Medica 2 Universitaria, Azienda Ospedaliero-Universitaria Pisana, via Roma 67, 56126 Pisa, Italy;7. Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy |
| |
| Abstract: | Background and aimThe aim of our retrospective study is to evaluate the prognostic significance of aspirin in patients with advanced HCC treated with sorafenib.Methods304 patients with HCC,consecutively treated with sorafenib from May 2007 to September 2018, were included in the clinical study. Of Them 93 patients token aspirin. Progression-free survival (PFS)and overall survival (OS)were estimated with the Kaplan–Meier method and compared with the log-rank test.ResultsThe concomitant use of sorafenib and aspirin was associated with a median OS of 18.3 months compared to 8.8 months of patients who did not receive aspirin (HR 0.57; P < 0.0001). The concomitant use of sorafenib and aspirin was associated with a median PFS of 7.3 months compared to 3.0 months of patients who did not receive aspirin (HR 0.61; P = 0.0003). In the multivariate analysis, the use of aspirin maintained an independent prognostic value for OS(HR 0.61; P = 0.0013). In second line the concomitant use of regorafenib and aspirin was associated with a median OS of 16.9 months compared to 8.0 months of patients who did not receive aspirin (HR 0.30; P = 0.02).ConclusionGlobally, our data seem to suggest that aspirin use may improve the clinical outcome of patients with advanced hepatocellular carcinoma receiving sorafenib and regorafenib. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
